WO2019109551A1 - Composition pharmaceutique contenant du carbonate d'aluminium de magnésium et utilisation pharmaceutique - Google Patents

Composition pharmaceutique contenant du carbonate d'aluminium de magnésium et utilisation pharmaceutique Download PDF

Info

Publication number
WO2019109551A1
WO2019109551A1 PCT/CN2018/080541 CN2018080541W WO2019109551A1 WO 2019109551 A1 WO2019109551 A1 WO 2019109551A1 CN 2018080541 W CN2018080541 W CN 2018080541W WO 2019109551 A1 WO2019109551 A1 WO 2019109551A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkaline phosphatase
pharmaceutical composition
magnesium aluminum
aluminum carbonate
powder
Prior art date
Application number
PCT/CN2018/080541
Other languages
English (en)
Chinese (zh)
Inventor
惠觅宙
Original Assignee
惠觅宙
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 惠觅宙 filed Critical 惠觅宙
Publication of WO2019109551A1 publication Critical patent/WO2019109551A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Definitions

  • the invention belongs to the technical field of medicine and relates to a new use of magnesium aluminum carbonate, in particular to a pharmaceutical composition containing magnesium aluminum carbonate, and a magnesium aluminum carbonate and a pharmaceutical composition thereof for preparing blood pressure lowering and/or lowering blood sugar and/or lowering The pharmaceutical use of blood lipids.
  • Sangao is a general term for high blood fat, high blood pressure and high blood sugar. Studies have shown that the aggregation of these three clinical diseases is not accidental. In 1988, the famous American endocrinologist Reaven described insulin resistance, hyperinsulinemia, impaired glucose tolerance, hypertriglyceridemia and hypertension in hyperlipidemia as "metabolic syndrome".
  • Metabolic syndrome refers to the pathological state in which the body's protein, fat, carbohydrate and other substances are metabolically disordered. It is a complex metabolic disorder syndrome and is a risk factor for cardiovascular and cerebrovascular diseases in diabetes. It has the following characteristics: ⁇ a variety of metabolic disorders in one, including obesity, hyperglycemia, hypertension, dyslipidemia, high blood viscosity, high uric acid, high fatty liver incidence and hyperinsulinemia, these metabolic disorders are the heart, Cerebrovascular disease and the pathological basis of diabetes. It can be seen that diabetes is not an isolated disease, but one of the components of the metabolic syndrome. ⁇ have a common pathological basis, and currently think that their common cause is obesity, especially insulin resistance and hyperinsulinemia caused by central obesity.
  • ⁇ can cause a variety of diseases, such as high blood pressure, coronary heart disease, stroke, and even some cancers, including sex hormone-related breast cancer, endometrial cancer, prostate cancer, and digestive system pancreatic cancer, hepatobiliary cancer, colon Cancer, etc.
  • diseases such as high blood pressure, coronary heart disease, stroke, and even some cancers, including sex hormone-related breast cancer, endometrial cancer, prostate cancer, and digestive system pancreatic cancer, hepatobiliary cancer, colon Cancer, etc.
  • ⁇ There are common preventive and therapeutic measures to prevent and treat a metabolic disorder, which is beneficial to the prevention and treatment of other metabolic disorders.
  • the etiology of metabolic syndrome has not yet been clarified. It is currently considered to be the result of interaction between multiple genes and multiple environments, and is closely related to heredity and immunity.
  • the disease is affected by a variety of environmental factors, concentrated in high-fat, high-carbohydrate dietary structure, increased insulin resistance, low labor intensity, less exercise and other metabolic syndrome.
  • Dyslipidemia fasting blood glycerol Ester ⁇ 1.7 mmol / L (150 mg / dl), and / or fasting blood HDL-C ⁇ 0.9 mmol / L (35 mg / dl) (male), ⁇ 1.0 mmol / L (39 mg / dl) (female). Three or all of the above four components can be diagnosed as metabolic syndrome.
  • Magnesium aluminocarbonate is a basic compound which is currently used in the acid and gastric mucosal protective drugs of the digestive system. It can be used for gastric ulcer and duodenal ulcer, acute and chronic gastritis and duodenal ampulla. Reflux esophagitis and stomach discomfort associated with hyperacidity, such as heartburn, acid reflux and bloating, nausea, vomiting and other symptomatic treatment.
  • Typical dosage forms are powders, tablets, suspensions, chewable tablets, suspensions, and the like.
  • Oral administration is generally 0.5 to 1.0 g each time, 3 times a day, between meals and before bedtime.
  • the names of commercialized drugs of magnesium aluminum carbonate include Talte and Wei Daxi.
  • magnesium aluminum carbonate can be used to lower blood pressure, blood sugar or blood lipids. It has not been reported in the literature that aluminum magnesium carbonate can be combined with other substances to treat metabolic syndrome or manifest as symptoms of hypertension, hyperglycemia or hyperlipemia.
  • the present invention has found a new use of magnesium aluminocarbonate based on scientific research, in particular the use of magnesium aluminum carbonate for the preparation of blood lowering and/or hypoglycemic and/or hypolipidemic drugs. Accordingly, it is an object of the present invention to provide a pharmaceutical composition containing magnesium aluminum carbonate and a pharmaceutical use.
  • the present invention adopts the following technical solutions:
  • a pharmaceutical composition comprising magnesium aluminum carbonate, the pharmaceutical composition comprising magnesium aluminum carbonate and an antidiarrheal agent.
  • the antidiarrheal agent is montmorillonite powder.
  • the weight ratio of the magnesium aluminum carbonate to the smectite powder is 2.5:1.
  • the pharmaceutical composition also contains alkaline phosphatase.
  • the alkaline phosphatase per 10,000 active units is compatible with 5 g of aluminum magnesium carbonate and montmorillonite powder.
  • the pharmaceutical composition also contains a surfactant.
  • the alkaline phosphatase employs a recombinant alkaline phosphatase obtained by recombinant DNA technology, or an alkaline phosphatase extracted from intestinal tissues of an animal.
  • the recombinant alkaline phosphatase is produced by recombinant DNA technology in Chinese hamster cells, Saccharomyces cerevisiae or Aspergillus niger.
  • the recombinant alkaline phosphatase is a recombinant human intestinal mucosal surface alkaline phosphatase having an amino acid sequence as shown in SEQ ID No. 4, and a recombinant human placental alkaline phosphatase or amino acid having an amino acid sequence as shown in SEQ ID No. 5.
  • the sequence is the recombinant human mosaic type alkaline phosphatase shown in SEQ ID No. 6.
  • the alkaline phosphatase is a lyophilized powder.
  • the pharmaceutical composition is a powder, a tablet or a capsule.
  • a clinical dietary supplement comprising the pharmaceutical composition further comprising a meal or starch.
  • each 10 grams of tantalum powder or starch is compatible with a sum of 15 g of aluminum magnesium carbonate and montmorillonite powder.
  • the invention also protects the use of magnesium aluminocarbonate in the manufacture of a medicament for lowering blood pressure and/or lowering blood glucose and/or lowering blood fat.
  • the invention also protects the use of a combination of magnesium aluminum carbonate and montmorillonite for the manufacture of a medicament for lowering blood pressure and/or lowering blood glucose and/or lowering blood fat.
  • the invention also protects the use of a combination of aluminum magnesium carbonate, montmorillonite and alkaline phosphatase for the manufacture of a medicament for lowering blood pressure and/or lowering blood glucose and/or lowering blood lipids.
  • the pharmaceutical composition containing magnesium aluminum carbonate provided by the present invention can be significantly reduced in blood glucose, blood pressure and blood lipid level of the subject by in vivo experiments, and the new use of magnesium aluminum carbonate can be applied.
  • Figure 1 shows the pH range of different parts of the digestive tract of normal people.
  • Figure 2 is a SDS-PAGE electropherogram of recombinant human mosaic alkaline phosphatase obtained using different methods. (Where: High-purity recombinant human mosaic-type alkaline phosphatase obtained using CHO cells: SDS-PAGE electrophoresis.
  • the third and sixth non-reducing 120KD stains are mosaic-type alkaline phosphatase homologs, lane 4
  • the reduced 60KD staining spot is a mosaic type alkaline phosphatase monomer
  • the first non-reducing 120KD and 60KD staining spots are mosaic type alkaline
  • the phosphatase homologous and mosaic-type alkaline phosphatase monomers are basically identical to the high-purity recombinant human mosaic electrophoresis obtained using CHO cells, except that the purity of the enzyme protein is relatively poor; the purified protein obtained using Aspergillus niger Recombinant human mosaic alkaline phosphatase: SDS-PAGE electrophoresis
  • the second non-reducing 120KD and 60KD staining spots are mosaic alkaline phosphata
  • the inventors unexpectedly discovered that a large amount of oral magnesium aluminocarbonate reduces blood sugar and blood pressure in a subject with hyperglycemia, hypertension, and/or hyperlipidemia in a combination of magnesium aluminocarbonate and other drugs for the treatment of reflux larynx. Or blood lipid levels, and the effect is more significant. Subsequently, it was confirmed by in vivo experiments that a large dose of magnesium aluminum carbonate did have blood pressure lowering and/or blood sugar lowering and/or hypolipidemic activity, and side effects of diarrhea were also found.
  • the inventors have confirmed that the combination of magnesium aluminocarbonate or a combination of the antidiarrheal montmorillonite powder can alleviate the side effects of diarrhea, but there is a slight bloating, and further, the inventors have developed a clinical diet which can reduce bloating. Agent. Further, the inventors used magnesium magnesium carbonate powder, montmorillonite powder and human alkaline phosphatase in combination or in combination, and found that the treatment of hyperglycemia, hyperlipemia and hypertension is more effective, and does not cause other additional side effects.
  • METHODS Ten “three high” subjects with hyperglycemia, hyperlipidemia and hypertension were included, including 7 males and 3 females, aged 54 ⁇ 6 years. The subjects received a large amount of oral magnesium magnesium carbonate before meals, 10 grams each time.
  • Table 5 The decrease in total cholesterol and triglycerides of blood after 4 weeks of high consumption of magnesium aluminum carbonate powder before meals.
  • OBJECTIVE To solve the side effects of diarrhea and increased stool frequency in the treatment of magnesium aluminocarbonate in Examples 1 and 2 using the antidiarrheal montmorillonite powder.
  • Table 8 The reduction of total cholesterol and triglyceride in blood after 4 weeks of treatment with magnesium montmorillonite powder before meals.
  • Table 9 The decrease in blood pressure diastolic blood pressure after 4 weeks of treatment with a large amount of magnesium montmorillonite powder before three meals.
  • OBJECTIVE To treat the clinical effects of hyperglycemia, hyperlipemia and hypertension with clinical diet containing magnesium aluminum carbonate and montmorillonite powder and to observe clinical side effects.
  • METHODS Ten “three high” subjects with hyperglycemia, hyperlipidemia and hypertension were enrolled in the study. There were 6 males and 4 females, aged 58 ⁇ 6 years. Subjects received 25 grams of a meal containing magnesium aluminum carbonate and montmorillonite powder three meals before meals. The clinical diet containing magnesium aluminum carbonate and montmorillonite powder contains 15 g of magnesium aluminum montmorillonite powder (10.72 g of magnesium aluminum carbonate, 4.28 g of montmorillonite), 10 g of glutinous powder or starch.
  • Table 11 Decreased total cholesterol and triglycerides after 4 weeks of clinical dietary treatment with magnesium aluminum carbonate and montmorillonite powder before meals.
  • METHODS Modern human consumption of meat and fatty foods increased significantly, while oils and meats induced increased gastric acid secretion and decreased normal intestinal pH (Figure 1). Increased gastric acid secretion is also easy to cause reflux throat disease. These patients are overweight or obese and suffer from "three highs”, namely high blood sugar, high blood fat, and high blood pressure.
  • Table 13 shows the pH level of various parts of the intestine using BRAVO Radiotelemetry PH Capsules before and after treatment with a large number of oral magnesium aluminophosphate montmorillonite powder in patients with reflux and throat disease, indicating that magnesium montmorillonite powder is significantly elevated.
  • the pH levels of the small and large intestines are high.
  • magnesium aluminum carbonate powder or mixed aluminum magnesium sulphate powder may activate alkaline phosphatase activity on the intestinal surface by increasing the pH of the intestinal surface (Table 14). Moreover, the amount of inactivated endotoxin in the same alkaline phosphatase sample at different pH values should also be different (Table 15).
  • the active region of the endotoxin has two phosphate groups, the alkaline phosphatase can remove one of the phosphate groups, and the endotoxin toxicity of the phosphate group containing an active region is substantially eliminated.
  • a large amount of oral magnesium aluminophosphate montmorillonite powder increased the pH level of the small intestine and large intestine mucosa before meals; 2.
  • Aluminum magnesium montmorillonite powder effectively activated alkaline phosphatase activity by increasing pH;
  • Magnesium aluminum sulphate powder increases the activity of alkaline phosphatase by increasing the pH value, and promotes the endotoxin inactivation;
  • a large amount of oral magnesium aluminophosphate montmorillonite powder before meals is effective for treating hyperglycemia, hyperlipemia and hypertension.
  • Alkaline phosphatase on the mucosal surface of the mucosa inactivates bacterial endotoxin mediated.
  • Method 1 Based on the methods described in the patent documents CN102124019A and WO2008/091276, recombinant human mosaic-type alkaline phosphatase is produced using animal cells (CHO cells). It mainly includes: cDNA of alkaline phosphatase and placental alkaline phosphatase which are recombinant human intestinal mucosal surface (see nucleotide sequence for SEQ ID No. 1 and SEQ ID No. 2, amino acid sequence for SEQ ID No. 4 and SEQ ID No. 5) was synthesized into recombinant human mosaic-type alkaline phosphatase cDNA (see SEQ ID No. 3 for nucleotide sequence and SEQ ID No.
  • Results 1 The SDS-PAGE electrophoresis results of Figure 2 showed that high purity recombinant human mosaic alkaline phosphatase was produced using CHO cells.
  • the high-purity recombinant human mosaic alkaline phosphatase produced by the obtained animal cells (CHO cells) and the food-grade surfactant for promoting absorption are combined into an enteric capsule. Or as a clinical dietary powder.
  • the obtained high-purity recombinant human mosaic alkaline phosphatase produced by animal cells (CHO cells) is made into a lyophilized powder, and mixed with aluminum magnesium carbonate and montmorillonite powder to prepare a compound preparation, which is hereinafter referred to as compound alkaline phosphatase aluminum carbonate.
  • Magnesium montmorillonite powder Magnesium montmorillonite powder.
  • the samples prepared above were used for subsequent examples. In practical applications, other forms such as powders, tablets, suspensions, and the like can be prepared as needed.
  • OBJECTIVE 2 Preparation of recombinant human mosaic-type alkaline phosphatase and recombinant human intestinal mucosal surface alkaline phosphatase in Saccharomyces cerevisiae.
  • Method 2 Synthetic recombinant human mosaic-type alkaline phosphatase cDNA (see SEQ ID No. 3 for nucleotide sequence, SEQ ID No. 6 for amino acid sequence) and recombinant human intestine by cooperation with Saccharomyces cerevisiae expression laboratory
  • the gene cDNA of the alkaline mucosal surface alkaline phosphatase (see SEQ ID No. 1 for the nucleotide sequence and SEQ ID No. 4 for the amino acid sequence) was inserted into the S. cerevisiae expression vector pYEAST to prepare pYEAST-mosaic alkaline phosphatase and pYEAST.
  • -rhIAP recombinant human intestinal mucosal surface alkaline phosphatase
  • the selected mosaic alkaline phosphatase and the recombinant human intestinal mucosal surface alkaline phosphatase high expression cell line are cultured in a large scale in a fermenter; after being separated and purified in multiple steps, a recombinant human having a purity of about 50.0-55.0% is prepared.
  • Results 2 The results of electrophoresis showed that recombinant human mosaic alkaline phosphatase and recombinant human intestinal mucosal surface alkaline phosphatase were successfully produced using food grade Saccharomyces cerevisiae.
  • the obtained recombinant human mosaic alkaline phosphatase and recombinant human intestinal mucosal surface alkaline phosphatase and a food-grade surfactant for promoting absorption for example, sucrose fatty acid ester, Tween 80, etc.
  • a food-grade surfactant for promoting absorption for example, sucrose fatty acid ester, Tween 80, etc.
  • Capsules or as a clinical dietary powder Using the obtained recombinant human mosaic alkaline phosphatase and the recombinant human intestinal mucosal surface alkaline phosphatase are respectively made into lyophilized powder, and respectively mixed with aluminum magnesium carbonate and montmorillonite powder to prepare a compound preparation, that is, compound alkaline phosphoric acid Enzyme aluminum magnesium montmorillonite powder.
  • the samples prepared above were used for subsequent examples.
  • Objective 3 Preparation of recombinant human mosaic alkaline phosphatase and recombinant human placental alkaline phosphatase using Aspergillus niger production.
  • Method 3 Synthetic recombinant human mosaic-type alkaline phosphatase (see SEQ ID No. 3 for nucleotide sequence, SEQ ID No. 6 for amino acid sequence) and recombinant human placenta base by cooperation with the Aspergillus expression laboratory The gene cDNA of the phosphatase (see SEQ ID No. 2 for the nucleotide sequence and SEQ ID No.
  • Electrophoretic staining results showed that recombinant human mosaic alkaline phosphatase and recombinant human placental alkaline phosphatase produced by food grade Aspergillus niger were used.
  • the obtained recombinant human mosaic alkaline phosphatase and recombinant human placental alkaline phosphatase are respectively combined with food-grade surfactants for promoting absorption (for example, sucrose fatty acid ester, Tween 80, etc.), and are filled into enteric capsules or Used as a clinical dietary powder.
  • the obtained recombinant human mosaic alkaline phosphatase and recombinant human placental alkaline phosphatase are respectively made into lyophilized powder, and respectively mixed with aluminum magnesium carbonate and montmorillonite powder to prepare a compound preparation, that is, compound alkaline phosphatase aluminum carbonate Magnesium montmorillonite powder.
  • the samples prepared above were used for subsequent examples.
  • Objective 4 Extract alkaline phosphatase using the small intestine of pigs.
  • Method 4 Extraction method of porcine intestinal alkaline phosphatase: 1. Take fresh pig small intestine and scrape the mucous membrane of fresh pig small intestine. 2. Add ice-cold distilled water and ice-cold n-butanol in the small intestinal mucosa, and homogenize at high speed. 3. The homogenate is placed in a centrifuge tube for centrifugation (4 ⁇ conditions, centrifuged at 10,000 rpm for 15 min). 4. In addition to impurities, liquid separation, static stratification, remove the lower aqueous phase, adjust the pH to 4.9 with 1 mol/L HAc, and centrifuge (4 ⁇ condition, 10000 rpm).
  • the supernatant was adjusted to pH 6.5 with 1mol / L NaOH, add 5% ammonium sulfate mass of the solution volume, dissolved; add appropriate amount of ice-cold acetone, mix, 4 ⁇ let stand for more than 30min, centrifuge (4 ⁇ condition, 10,000 rpm). 6. Obtain the supernatant, add an appropriate amount of ice-cold acetone, place it for 4 minutes at 4 °, and centrifuge (4 ⁇ condition, 10000 rpm). 7. Dissolve all the precipitate in the equilibration buffer and store in 4 ⁇ for use. 8. The partially purified crude enzyme dissolved in the equilibration buffer is stored freeze-dried.
  • the alkaline phosphatase extracted from the small intestine of the pig and the food-grade surfactant for promoting absorption are combined into an enteric capsule or used as a clinical dietary powder.
  • the obtained alkaline phosphatase solution successfully extracted from the small intestine of the pig is made into a lyophilized powder, and mixed with aluminum magnesium carbonate and montmorillonite powder to prepare a compound preparation, that is, compound alkaline phosphatase aluminum magnesium montmorillonite powder.
  • the samples prepared above were used for subsequent examples.
  • the above methods 1, 2, 3, and 4 are recombinant human mosaic alkaline phosphatase produced by CHO cells, recombinant human mosaic alkaline phosphatase produced by Saccharomyces cerevisiae, and recombinant human intestinal mucosal surface alkali produced by Saccharomyces cerevisiae. Bioactive equivalence studies of sex phosphatase, recombinant human mosaic alkaline phosphatase produced by Aspergillus niger, recombinant human placental alkaline phosphatase produced by Aspergillus niger, and alkaline phosphatase extracted from pig small intestine.
  • Method 5 Recombinant human mosaic alkaline phosphatase produced by using the same amount of CHO cells prepared above, recombinant human mosaic alkaline phosphatase produced by Saccharomyces cerevisiae, recombinant human intestinal mucosal surface alkaline phosphoric acid produced by Saccharomyces cerevisiae Recombinant human mosaic alkaline phosphatase produced by enzyme, Aspergillus niger, recombinant human placental alkaline phosphatase produced by Aspergillus niger, and alkaline phosphatase extracted from pig small intestine under the same neutral pH and reaction conditions Equivalence study of endotoxin inactivation experiments.
  • Table 16 shows the same amount of different alkaline phosphatase. The effect of dephosphorylation of the phosphate group in the endotoxin active region was substantially the same under the same neutral pH and reaction conditions.
  • alkaline phosphatase prepared by different methods dephosphorization of the endotoxin active region (ie, the biological activity of alkaline phosphatase) is expressed by micromolar phosphorus release (uM Pi release).
  • Table 17 shows the results of diarrhea, increased stool frequency, and bloating.
  • Table 17 Diarrhea, increased stool frequency, and bloating in subjects taking 5 grams and 15 grams of magnesium aluminum montmorillonite powder before meals.
  • OBJECTIVE To optimize the pH environment by using a small amount of magnesium montmorillonite powder to create alkaline phosphatase activity, and to treat hyperglycemia, hyperlipemia and hypertension with combined or compound alkaline phosphatase.
  • METHODS A total of 40 "three high" subjects with hyperglycemia, hyperlipidemia and hypertension were enrolled in this study. There were 26 males and 14 females, aged 58 ⁇ 6 years, and were randomly divided into 4 groups, 10 in each group. Oral daily before three meals a day, each time using a small amount of 5 grams of aluminum magnesium montmorillonite powder or combination of alkaline phosphatase and absorption of surfactants (such as sucrose fatty acid ester, Tween 80, etc.) enteric Capsules treat hyperglycemia, hyperlipidemia, and hypertension; alkaline phosphatase is administered at 10,000 units each for 28 consecutive days. Results: See Tables 18, 19, 20.
  • Table 19 Decreased total cholesterol and triglycerides in blood after 4 weeks of treatment.
  • Table 21 shows 15 g of magnesium aluminum montmorillonite powder, 5 g of magnesium montmorillonite powder combined with alkaline phosphatase enteric-coated capsule group and alkaline phosphatase (10000 units) enteric-coated capsules alone. Results of a comparative experimental study of subjects in the diet.
  • Table 21 shows 15 g of magnesium aluminum montmorillonite powder, 5 g of magnesium aluminum montmorillonite powder combined with alkaline phosphatase enteric-coated capsule group and alkaline phosphatase (10000 units) enteric-coated capsule alone group to eat chili diet The subjects compared the results of the experimental study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant du carbonate d'aluminium de magnésium, qui comprend du carbonate d'aluminium de magnésium et un antidiarrhéique, et comprend également une phosphatase alcaline; un agent alimentaire clinique comprenant la composition pharmaceutique; et l'utilisation du carbonate d'aluminium de magnésium, ou d'une composition du carbonate d'aluminium de magnésium et de montmorillonite, ou d'une composition du carbonate d'aluminium de magnésium, de montmorillonite et de phosphatase alcaline dans la préparation de médicaments antihypertenseurs et/ou hypoglycémiques et/ou hypolipidémiques.
PCT/CN2018/080541 2017-12-08 2018-03-26 Composition pharmaceutique contenant du carbonate d'aluminium de magnésium et utilisation pharmaceutique WO2019109551A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711297440.8 2017-12-08
CN201711297440.8A CN107802642B (zh) 2017-12-08 2017-12-08 一种含有铝碳酸镁的药物组合物及制药用途

Publications (1)

Publication Number Publication Date
WO2019109551A1 true WO2019109551A1 (fr) 2019-06-13

Family

ID=61579649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/080541 WO2019109551A1 (fr) 2017-12-08 2018-03-26 Composition pharmaceutique contenant du carbonate d'aluminium de magnésium et utilisation pharmaceutique

Country Status (2)

Country Link
CN (1) CN107802642B (fr)
WO (1) WO2019109551A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107802642B (zh) * 2017-12-08 2020-07-24 惠觅宙 一种含有铝碳酸镁的药物组合物及制药用途
CN109459543A (zh) * 2018-12-21 2019-03-12 马德君 一种测试含镁无机抗酸剂体外抗酸性能的方法
CN114732828A (zh) * 2022-04-27 2022-07-12 广西南宁百会药业集团有限公司 一种铝碳酸镁混悬液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011084491A (ja) * 2009-10-14 2011-04-28 Kyowa Chem Ind Co Ltd 膵臓機能強化乃至活性化用ハイドロタルサイト類化合物粒子
CN107802642A (zh) * 2017-12-08 2018-03-16 惠觅宙 一种含有铝碳酸镁的药物组合物及制药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985697A1 (fr) * 2007-04-27 2008-10-29 AM-Pharma B.V. Phosphatases modifiées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011084491A (ja) * 2009-10-14 2011-04-28 Kyowa Chem Ind Co Ltd 膵臓機能強化乃至活性化用ハイドロタルサイト類化合物粒子
CN107802642A (zh) * 2017-12-08 2018-03-16 惠觅宙 一种含有铝碳酸镁的药物组合物及制药用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DI, YONGXIN: "Non-official translation: Observation of Curative Effect of Triple Therapy in the Treatment of 29 Cases with Bile Reflux Gastritis", JOURNAL OF NORTH PHARMACY, vol. 9, no. 5, 31 December 2012 (2012-12-31), pages 12 - 13 *
LIN, YICHAN ET AL.: "32 (Non-official translation: Analysis of 32 Cases with Diabetes Mellitus and Gastrointestinal Reaction", JOURNAL OF NORTH PHARMACY, vol. 9, no. 11, 31 December 2012 (2012-12-31), pages 67 *
MALO, M.S.: "A High Level of Intestinal Alkaline Phosphatase is Protective against Type 2 Diabetes Mellitus Irrespective of Obesity", EBIOMEDICINE, vol. 2, no. 12, 1 December 2015 (2015-12-01), pages 2016 - 2023, XP055498471, doi:10.1016/j.ebiom.2015.11.027 *
WANG, SHULING: "Study on the Treatment of Hydrotalcite on Bile Acid Assoicated Diarrhea", TIANJIN MEDICAL UNIVERSITY MASTER'S DISSERTATION, 1 May 2017 (2017-05-01) *

Also Published As

Publication number Publication date
CN107802642B (zh) 2020-07-24
CN107802642A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
JP6316501B2 (ja) アッカーマンシア・ムシニフィラ菌に由来する細胞外小胞を有効成分として含有する代謝疾患の治療または予防用の組成物
TWI380823B (zh) 脂聯素（Ａｄｉｐｏｎｅｃｔｉｎ）濃度上升劑
CN102670864B (zh) 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物
CN101715913B (zh) 一种调节血脂的胶囊及其生产制作工艺
WO2019109551A1 (fr) Composition pharmaceutique contenant du carbonate d'aluminium de magnésium et utilisation pharmaceutique
CN114209810B (zh) 枸杞糖肽在制备用于预防或治疗炎性肠病的药物中的用途
ES2949270T3 (es) Uso de un portador farmacéutico en la preparación de una composición farmacéutica antidiabética que comprende berberina y orizanol
CN107537028B (zh) 一种同时辅助降血糖及降血压的配方及其制备方法
CN110074392A (zh) 一种解酒保肝养胃护肠组合物及其制备方法
CN112457423B (zh) 一种具有改善胰岛素抵抗作用的天然提取复合多糖及应用
JP2024514745A (ja) ラクトバチルス・ムコサエと可溶性食物繊維との組み合わせを用いた方法および組成物
JP2014181232A (ja) Ａｓｐｅｒｇｉｌｌｕｓｏｒｙｚａｅを用いたトウガラシ発酵物の血糖値上昇抑制剤
KR100506950B1 (ko) 진세노사이드를 함유함을 특징으로 하는 면역증강효과에 대한 조성물
CN110771769A (zh) 一种辅助治疗二型糖尿病的壳寡糖复合固体饮料
CN106589083B (zh) 一种治疗酒精性肝病的云芝胞内糖肽活性成分PSK-1c1
CN101264203A (zh) 治疗糖尿病的中西药组合物
TWI439273B (zh) 以靈芝酸保護心臟免於壞死或損傷之方法與組成物
EP4094590A1 (fr) Procédés et compositions utilisant des combinaisons de lactobacillus mucosae et de fibres diététiques solubles
JP2006117566A (ja) 糖代謝改善剤
WO2019043700A1 (fr) Extrait de s. spinosum pour le traitement de la steatose hepatique
CN115252638B (zh) 一种改善肠道炎症的藜麦膳食纤维制备方法及应用
CN110787287B (zh) 一种鱼鳞胶原蛋白多肽在制备治疗慢性心力衰竭药物中的应用
CN104127545B (zh) 四数九里香及其提取物在制备药物中的应用
JP5007995B2 (ja) 海苔を用いた糖尿病治療剤
Jusni et al. Potential Antihyperlipidemia Effect of Lactoferrin in Hyperlipidemia-Induced Male Sprague–Dawley Rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18886617

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18886617

Country of ref document: EP

Kind code of ref document: A1